NCT03542682 is a NA clinical trial of Quick Bolus in Type1diabetes, sponsored by Yale University.

Who is sponsoring NCT03542682?

NCT03542682 is sponsored by Yale University.

What drugs are being tested in NCT03542682?

Interventions in NCT03542682: Quick Bolus, Standard Bolus.

What condition does NCT03542682 study?

NCT03542682 studies Type1diabetes.

Is NCT03542682 still recruiting?

NCT03542682 is currently completed. Last updated 13 February 2024.

Are results published for NCT03542682?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-02-13 · How we verify

NCT03542682

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Bolus Speed of Rapid-Acting Insulin Analog Absorption and Action in Individuals With Type 1 Diabetes

Completed NA Results posted Last updated 13 February 2024

What this trial tests

NA trial testing Quick Bolus in Type1diabetes in 11 participants. Completed in 23 September 2022.

Timeline

30 May 2018

Primary endpoint
23 September 2022

23 September 2022

Quick facts

Lead sponsor	Yale University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	basic science
Enrollment	11
Start date	30 May 2018
Primary completion	23 September 2022
Estimated completion	23 September 2022
Sites	1 location across United States

Drugs / interventions tested

Quick Bolus
Standard Bolus

Conditions studied

Type1diabetes — all drugs for Type1diabetes →

Sponsor

Yale University

Who can join

Adults 18 to 30, any sex, with Type1diabetes. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Time to Maximum Glucose Infusion Rate Primary · 300 minutes

time to maximum glucose infusion rate (GIR) in minutes

Group	Value	95% CI
Quick Bolus	116.54	74.74 – 158.34
Standard Bolus	172.21	130.41 – 214.01

Maximum Glucose Infusion Rate Secondary · 300 minutes

maximum glucose infusion rate (GIRmax)

Group	Value	95% CI
Quick Bolus	8.42	4.91 – 11.92
Standard Bolus	7.45	3.95 – 10.96

Area Under the Curve for the Glucose Infusion Rate Secondary · 300 minutes

area under the curve for the glucose infusion rate

Group	Value	95% CI
Quick Bolus	1204.29	716.72 – 1691.86
Standard Bolus	1072.44	584.86 – 1560.01

Adverse events — posted to ClinicalTrials.gov

Time frame: Up to 5 hours post intervention for each intervention. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Individuals Given Standard Bolus

Serious: 0/8 (0%)

Deaths: 0/8

Individuals Given Quick Bolus

Serious: 0/9 (0%)

Deaths: 0/9

Other adverse events (1 terms — click to expand)

Reaction	System	Individuals Given Standard…	Individuals Given Quick Bo…
Common Cold	Infections and infestations	—	—

Data from ClinicalTrials.gov NCT03542682 adverse events section.

Sponsor's own description

Rapid Action Insulin (RAI) absorption and action measured by time to reach maximum insulin concentration and glucose infusion rate.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Type1diabetes

Currently open trials in the same condition.

NCT07139808 — Safety and Effectiveness of A Novel Continuous Glucose and Ketone Monitoring System · NA · recruiting
NCT07092761 — Evaluation of the Accuracy and Safety of A Novel Real-Time Continuous Glucose Monitoring System · NA · recruiting
NCT06646107 — Adherence to Mediterranean Diet in Type 1 Diabetes Initiating Minimed 780G: Glucose Metrics vs Insulin Metrics, is There · recruiting
NCT06753994 — Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors · Phase 1 · recruiting
NCT05668507 — REACHOUT Mental Health Support Mobile App · NA · active not recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03542682 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 13 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03542682.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing